AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Cardiff Lexington Corporation

$0.25 -$5.33 (-95.52%)
OTC · 14 Sep 2026 15:39 UTC
Previous Close
$0.25
Day Range
$0.25$0.25
Year Range
$0.12$6
Market Cap
1.73M
AVG Volume
4.34K
Trailing/Forward PE
-0.25/-
PEG ratio
0.04
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD) · TTM
05M10M15M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q210.21M
26 Q110.84M
25 Q411.54M
25 Q311.88M
25 Q210.18M
25 Q18.86M
24 Q48.27M
24 Q37.22M
24 Q29.27M
24 Q111.16M
Net Income (USD) · TTM
-15M-10M-5M05M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-10.44M
26 Q1-9.18M
25 Q4-6.54M
25 Q3-3.73M
25 Q2-4.57M
25 Q1-3.47M
24 Q4-3.3M
24 Q3-2.15M
24 Q21.81M
24 Q12.76M
Operating Income (USD) · TTM
-2M02M4M6M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-1.11M
26 Q145.49K
25 Q41.1M
25 Q32.13M
25 Q2900.6K
25 Q1131.44K
24 Q4-193.5K
24 Q3-20.32K
24 Q22.84M
24 Q14.75M
EBITDA (USD) · TTM
-4M-2M02M4M6M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-2.21M
26 Q1-1.05M
25 Q45.65K
25 Q32.11M
25 Q2902.45K
25 Q1216.44K
24 Q4-107.9K
24 Q3132.03K
24 Q22.98M
24 Q14.79M
Cash Flows (USD) · TTM
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-2.77M
26 Q1-3.52M
25 Q4-3.99M
25 Q3-3.19M
25 Q2-4.66M
25 Q1-4.05M
24 Q4-4.49M
24 Q3-3.74M
24 Q2-3.13M
24 Q1-2.45M
EPS (USD) · TTM
-10010203024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-1.02
26 Q1-1.08
25 Q4-0.98
25 Q3-0.81
25 Q2-1.08
25 Q1-0.95
24 Q4-1.14
24 Q39.58
24 Q216.96
24 Q128.32
Expenses (USD) · TTM
-2M02M4M6MSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q25.49M
26 Q15.22M
25 Q45.33M
25 Q35.32M
25 Q24.99M
25 Q14.74M
24 Q44.61M
24 Q33.56M
24 Q23.2M
24 Q12.9M
Shares Outstanding · TTM
-2M-1.5M-1M-500K0500K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CDIX Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q2-1.67M
26 Q1-1.31M
25 Q4-642.01K
25 Q327.23K
25 Q20
25 Q111.62K
24 Q4-776.98K
24 Q3-776.98K
24 Q2-776.98K
24 Q1-788.6K
Employee Count
0204060802016201720182019202020212022202320242025
CDIX Employee Count by quarter
PeriodEmployee Count
202518
202413
202310
202210
202119
202037
201972
201870
201740
201640
PE Ratio
02.557.51012.5med 0.08Dec 20Feb 21Mar 21Jan 23Mar 23Apr 23May 24
CDIX PE Ratio by quarter
PeriodPE Ratio
May 249.68
May 2410.02
May 244.84
May 240.09
Apr 240.17
May 230.04
May 230.04
Apr 230.04
Apr 230.12
Apr 230.16
Apr 230.16
Mar 230.12
Mar 230.08
Mar 230.12
Mar 230.12
Mar 230.1
Feb 230.24
Feb 230.33
Feb 230.37
Feb 230.41
Jan 230.33
Jan 230.53
Jan 230.82
Jan 230.82
Dec 220.06
Dec 220.06
Dec 220.06
Dec 220.06
Mar 210.04
Mar 210.05
Mar 210.06
Mar 210.03
Feb 210.08
Feb 210.1
Feb 210.11
Feb 210.05
Jan 210.06
Jan 210.11
Jan 210.05
Jan 210.05
Dec 200.04
Dec 200.07
Dec 200.04
Dec 200.06
Dec 200.04
Nov 200.04
Nov 200.07
Free Cash Flow Yield
-8000%-6000%-4000%-2000%0%med -19.46%Jun 23Oct 23Feb 24Jul 25Oct 25Feb 26Sep 26
CDIX Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-37.04%
Sep 26-97.8%
Sep 26-156.17%
Aug 26-90.74%
Aug 26-90.74%
Aug 26-45.83%
Aug 26-47.84%
Jul 26-41.2%
Jul 26-34.58%
Jul 26-26.9%
Jul 26-16.14%
Jul 26-16.14%
Jun 26-13.83%
Jun 26-17.17%
Feb 26-12.07%
Feb 26-10.76%
Feb 26-9.58%
Jan 26-9.68%
Jan 26-12.04%
Jan 26-11.2%
Jan 26-12.41%
Jan 26-8.67%
Dec 25-9.11%
Dec 25-9.49%
Dec 25-9.49%
Dec 25-10.76%
Nov 25-13.79%
Nov 25-29.33%
Nov 25-12.41%
Nov 25-16.56%
Oct 25-24.6%
Oct 25-16.56%
Oct 25-15.33%
Oct 25-15.33%
Oct 25-16.56%
Sep 25-16.24%
Sep 25-6.21%
Sep 25-16.56%
Sep 25-16.56%
Aug 25-16.56%
Aug 25-16.56%
Aug 25-17.64%
Aug 25-13.23%
Aug 25-19.46%
Jul 25-19.46%
Jul 25-19.46%
Feb 25-4.09%
Dec 24-8.58%
Dec 24-4.09%
Nov 24-4.09%
May 24-9.16%
May 24-8.84%
May 24-18.32%
May 24-607.19%
Apr 24-323.83%
Mar 24-17.82%
Mar 24-23.16%
Mar 24-74.72%
Mar 24-77.21%
Feb 24-77.21%
Feb 24-77.21%
Jan 24-38.61%
Jan 24-28.95%
Jan 24-23.16%
Jan 24-7.72%
Dec 23-7.72%
Dec 23-7.72%
Dec 23-7.72%
Dec 23-7.72%
Dec 23-3.86%
Nov 23-2.21%
Nov 23-1.93%
Nov 23-34.8%
Nov 23-34.8%
Oct 23-17.4%
Oct 23-1118.28%
Oct 23-1118.28%
Sep 23-1118.28%
Sep 23-1118.28%
Sep 23-1118.28%
Aug 23-1118.28%
Aug 23-1118.28%
Aug 23-559.14%
Aug 23-559.14%
Jul 23-447.31%
Jul 23-559.14%
Jul 23-279.57%
Jul 23-279.57%
Jun 23-186.38%
Jun 23-1007.1%
Jun 23-1007.1%
May 23-6080.69%
May 23-6080.69%
Apr 23-6080.69%
Apr 23-2026.9%
Apr 23-1520.17%
Apr 23-1520.17%
Mar 23-2026.9%
Mar 23-3040.34%
Mar 23-2026.9%
Price to Sales
051015med 1.07Jun 23Oct 23Feb 24Jul 25Oct 25Feb 26Sep 26
CDIX Price to Sales by quarter
PeriodPrice to Sales
Sep 260.73
Sep 260.28
Sep 260.17
Aug 260.3
Aug 260.3
Aug 260.59
Aug 260.68
Jul 260.79
Jul 260.94
Jul 261.21
Jul 262.01
Jul 262.01
Jun 262.34
Jun 261.89
Feb 262.22
Feb 262.49
Feb 262.8
Jan 262.77
Jan 262.23
Jan 262.39
Jan 262.16
Jan 263.09
Dec 252.94
Dec 252.83
Dec 252.83
Dec 252.49
Nov 251.94
Nov 250.91
Nov 252.16
Nov 252.76
Oct 251.86
Oct 252.76
Oct 252.98
Oct 252.98
Oct 252.76
Sep 252.82
Sep 257.37
Sep 252.76
Sep 252.76
Aug 252.76
Aug 252.76
Aug 252.59
Aug 253.46
Aug 252.35
Jul 252.35
Jul 252.35
Feb 2512.67
Dec 246.04
Dec 2412.67
Nov 2412.67
May 242.39
May 242.48
May 241.2
May 240.02
Apr 240.05
Mar 240.46
Mar 240.36
Mar 240.11
Mar 240.11
Feb 240.11
Feb 240.11
Jan 240.21
Jan 240.29
Jan 240.36
Jan 241.07
Dec 231.07
Dec 231.07
Dec 231.07
Dec 231.07
Dec 232.14
Nov 233.75
Nov 234.28
Nov 230.24
Nov 230.24
Oct 230.48
Oct 230.01
Oct 230.01
Sep 230.01
Sep 230.01
Sep 230.01
Aug 230.01
Aug 230.01
Aug 230.01
Aug 230.01
Jul 230.02
Jul 230.01
Jul 230.03
Jul 230.03
Jun 230.04
Jun 230.01
Jun 230.01
May 230
May 230
Apr 230
Apr 230
Apr 230.01
Apr 230.01
Mar 230
Mar 230
Mar 230
EV/EBITDA
0200400600800med 2.66Feb 23Jun 23Oct 23Feb 24Jul 25Nov 25Feb 26
CDIX EV/EBITDA by quarter
PeriodEV/EBITDA
Feb 2619.68
Feb 2621.21
Feb 2622.92
Jan 2622.76
Jan 2619.71
Jan 2620.65
Jan 2619.34
Jan 2624.57
Dec 2523.73
Dec 2523.08
Dec 2523.08
Dec 2521.21
Nov 2518.12
Nov 2512.32
Nov 2519.34
Nov 2545.59
Oct 2535.41
Oct 2545.59
Oct 2548.08
Oct 2548.08
Oct 2545.59
Sep 2546.21
Sep 2597.54
Sep 2545.59
Sep 2545.59
Aug 2545.59
Aug 2545.59
Aug 25153.5
Aug 25188.88
Aug 25143.59
Jul 25143.59
Jul 25143.59
Feb 25743.92
Dec 24381.46
Dec 24743.92
Nov 24743.92
May 246.98
May 247.18
May 244.19
May 241.11
Apr 241.16
Mar 243.16
Mar 242.75
Mar 241.8
Mar 241.79
Feb 241.79
Feb 241.79
Jan 242.2
Jan 242.47
Jan 242.75
Jan 245.49
Dec 235.49
Dec 235.49
Dec 235.49
Dec 235.49
Dec 239.61
Nov 2315.79
Nov 2317.85
Nov 231.81
Nov 231.81
Oct 232.57
Oct 231.24
Oct 231.24
Sep 231.24
Sep 231.24
Sep 231.24
Aug 231.24
Aug 231.24
Aug 231.26
Aug 231.26
Jul 231.28
Jul 231.26
Jul 231.32
Jul 231.32
Jun 231.37
Jun 231.2
Jun 231.2
May 230.36
May 230.36
Apr 230.36
Apr 230.36
Apr 230.36
Apr 230.36
Mar 230.36
Mar 230.36
Mar 230.36
Mar 230.36
Mar 230.36
Feb 230.37
Feb 230.37
Feb 230.37
Feb 230.38
Jan 230.37
Jan 230.38
Jan 230.4
Jan 230.4
Dec 220.42
Dec 220.42
Dec 220.42
Dec 220.42
Price to Book
0255075100med 3.75Jan 23Apr 23Feb 24Jul 25Oct 25Feb 26Sep 26
CDIX Price to Book by quarter
PeriodPrice to Book
Sep 262.09
Sep 260.79
Sep 260.5
Aug 260.85
Aug 260.85
Aug 261.69
Aug 261.3
Jul 261.51
Jul 261.8
Jul 262.31
Jul 263.85
Jul 263.85
Jun 264.49
Jun 263.62
Feb 265.27
Feb 265.91
Feb 266.63
Jan 266.57
Jan 265.28
Jan 265.67
Jan 265.12
Jan 267.33
Dec 256.97
Dec 256.7
Dec 256.7
Dec 255.91
Nov 254.61
Nov 252.17
Nov 255.12
Nov 2537.32
Oct 2525.13
Oct 2537.32
Oct 2540.31
Oct 2540.31
Oct 2537.32
Sep 2538.07
Sep 2599.53
Sep 2537.32
Sep 2537.32
Aug 2537.32
Aug 2537.32
Aug 2511.28
Aug 2515.04
Aug 2510.23
Jul 2510.23
Jul 2510.23
Feb 2524.53
Dec 2411.7
Dec 2424.53
Nov 2424.53
May 243.69
May 243.82
May 241.84
May 240.04
Apr 240.08
Mar 245.73
Mar 244.41
Mar 241.37
Mar 241.32
Feb 241.32
Feb 241.32
Jan 242.64
Jan 243.53
Jan 244.41
Jan 2413.22
Dec 2313.22
Dec 2313.22
Dec 2313.22
Dec 2313.22
Dec 2326.45
Nov 2346.28
Nov 2352.89
May 230
May 230
Apr 230
Apr 230.01
Apr 230.01
Apr 230.01
Mar 230.01
Mar 230.01
Mar 230.01
Mar 230.01
Mar 230.01
Feb 230.02
Feb 230.03
Feb 230.03
Feb 230.03
Jan 230.03
Jan 230.04
Jan 230.07
Jan 230.07
Dec 220.09
Dec 220.09
Dec 220.09
Dec 220.09
Dec 220.08
Nov 220.08
Oct 220.66
Oct 220.04
Oct 220.04
Cardiff Lexington Corporation
CDIX
Stockpicker

Video analysis: CDIX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CDIX

Cardiff Lexington Announces Second Quarter 2026 Financial Results

accessnewswire.com · 12 Aug 2026

Cardiff Lexington Announces Second Quarter 2026 Financial Results

LEXINGTON, KY / ACCESS Newswire / August 12, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "During the first half of 2026, we continued to execute on our long-term strategy to establish Nova Ortho and Spine as a leading healthcare network and provide best-in-class care to a severely underserved patient population.

Cardiff Lexington to Report Second Quarter 2026 Financial Results and Host Conference Call on Wednesday, August 12, 2026

accessnewswire.com · 6 Aug 2026

Cardiff Lexington to Report Second Quarter 2026 Financial Results and Host Conference Call on Wednesday, August 12, 2026

LEXINGTON, KY / ACCESS Newswire / August 6, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that the Company will host an investor conference call to discuss its financial and operating results for the second quarter ended June 30, 2026, on Wednesday, August 12, 2026, at 11:00 am ET. The Company will release its financial and operating results for the second quarter ended June 30, 2026, prior to the call on Wednesday, August 12, 2026.

Cardiff Lexington Announces the Addition of Southeastern Surgery Center in Tallahassee, Florida to Nova Ortho and Spine Network

accessnewswire.com · 29 Jun 2026

Cardiff Lexington Announces the Addition of Southeastern Surgery Center in Tallahassee, Florida to Nova Ortho and Spine Network

- Adds high visibility metropolitan location with potential for high patient volume - - 12th surgical center as company executes strategy to expand network throughout southeast and mid-Atlantic region - LEXINGTON, KY / ACCESS Newswire / June 29, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that its Nova Ortho and Spine subsidiary has added Southeastern Surgery Center in Tallahassee, Florida to its growing network of surgical facilities, enhancing access to advanced orthopedic and spine care for patients in this region. Southeastern Surgery Center has earned a strong reputation over many years of operation, recognized for its commitment to exceptional patient care, outstanding patient satisfaction, and stringent patient safety standards.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.